Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report

Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is ess...

Descripción completa

Detalles Bibliográficos
Autores principales: Koroku, Miki, Omori, Teppei, Kambayashi, Harutaka, Murasugi, Shun, Kuriyama, Tomoko, Ikarashi, Yuichi, Yonezawa, Maria, Arimura, Ken, Karasawa, Kazunori, Hanafusa, Norio, Kawana, Masatoshi, Tokushige, Katsutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831771/
https://www.ncbi.nlm.nih.gov/pubmed/33902268
http://dx.doi.org/10.5217/ir.2020.00148
Descripción
Sumario:Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.

Ejemplares similares